How did the divestiture of DuPont Pharmaceuticals impact the company's financial results?

The sale of DuPont Pharmaceuticals in October 2001 had a significant impact. It contributed a substantial gain to net income in 2001, boosting that year's results. Consequently, its absence in 2002 led to lower net sales and reduced R&D expenses, as the pharmaceutical segment was research-intensive. The sale also resulted in significant tax payments in 2002 related to the gain realized in 2001.

What is the status of the litigation concerning Benlate(R) fungicide?

The litigation related to Benlate(R) fungicide is ongoing. As of December 31, 2002, there were 104 pending cases, involving allegations of crop damage, fraud, misconduct, personal injuries, and damage to shrimping operations. The company has incurred significant costs related to these matters (approximately $1.7 billion to date) and has established reserves for estimated future costs, though it believes Benlate(R) did not cause the alleged damages.

What is the company's outlook for 2003, and what are the key factors influencing it?

The company expected 2003 earnings per share to reflect increased sales volumes, barring significant economic disruptions. Key influencing factors included anticipated global GDP growth, a recovery in the manufacturing sector, continued efforts in cost control, and the benefits from ongoing research and development. However, it also anticipated negative impacts from pension and post-retirement expenses, a return to historical income tax rates, and the adoption of new accounting standards. The long-term growth prospects were tied to global economic growth, market conditions, new product commercialization, and the successful separation of the Textiles & Interiors segment.

CTA-PB/CTA-PA 10-K FY2002 Annual Report — Revenue, Net Income, EPS

Q: What was the primary driver behind EIDP, Inc.'s net loss in 2002?

The primary driver for the net loss of $1,103 million in 2002 was a significant charge of $2,944 million related to the cumulative effect of a change in accounting principle for goodwill impairment. Additionally, various 'special items' amounting to $168 million (net after-tax) contributed to the negative financial result.

Summary

EIDP, Inc. (CTA-PB), in its 2002 Form 10-K filing from February 2003, reported a net loss of $1,103 million for the fiscal year ended December 30, 2002. This contrasts with a significant net income of $4,339 million in 2001. The substantial loss in 2002 was primarily attributed to a $2,944 million charge related to the cumulative effect of a change in accounting principle for goodwill impairment, alongside various "special items" that resulted in net after-tax charges totaling $168 million. Net sales for 2002 were $24.0 billion, a slight decrease from $24.7 billion in 2001, impacted by portfolio changes including the divestiture of DuPont Pharmaceuticals and Clysar shrink film business, partially offset by acquisitions. The company's operational performance was influenced by mixed segment results. While some areas like Agriculture & Nutrition and Safety & Protection showed improvements or resilience, others such as Textiles & Interiors and Electronic & Communication Technologies experienced declines due to market conditions and restructuring efforts. Significant restructuring programs were underway in 2002, particularly in Coatings & Color Technologies and Textiles & Interiors, aimed at improving competitiveness and aligning resources. The company highlighted its continued commitment to research and development, though R&D expenses decreased from prior years largely due to the divestiture of its pharmaceuticals segment.

Key Highlights

1EIDP, Inc. reported a net loss of $1,103 million for the fiscal year 2002, a significant downturn from a net income of $4,339 million in 2001.

2A major factor in the 2002 net loss was a $2,944 million charge for the cumulative effect of a change in accounting principle related to goodwill impairment.

3Consolidated net sales decreased by 3% to $24.0 billion in 2002, influenced by divestitures (e.g., DuPont Pharmaceuticals) and acquisitions.

4The company initiated substantial restructuring programs in 2002 within segments like Coatings & Color Technologies and Textiles & Interiors to improve efficiency and competitiveness.

5Research and Development (R&D) expenses decreased to $1,264 million in 2002 from $1,588 million in 2001, largely due to the divestiture of the pharmaceuticals segment.

6The company maintained a strong liquidity position, with cash and cash equivalents and marketable debt securities totaling $4.1 billion at year-end 2002, though this was a decrease from the previous year primarily due to tax payments related to the DuPont Pharmaceuticals sale.

7Significant legal proceedings related to the Benlate(R) fungicide continued, with ongoing litigation and accruals for estimated future costs.

Frequently Asked Questions